GCIA
SAGE

Gabelli & Co Investment Advisers’s Sage Therapeutics SAGE Stock Holding History

Gabelli & Co Investment Advisers’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-224,450
Closed -$2.05M – 318
2025
Q2 		$2.05M Buy
+224,450
New +$1.65M 0.31% 68

Other funds holding SAGE

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Gabelli & Co Investment Advisers's SAGE Position: Q3 2025 in Review

Gabelli & Co Investment Advisers sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 224,450 shares — an estimated $2.05M sold.

Gabelli & Co Investment Advisers first reported a position in SAGE in Q2 2025 and held it in 1 quarter. The position peaked at $2.05M in Q2 2025. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.

  • Gabelli & Co Investment Advisers reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Gabelli & Co Investment Advisers sold 224,450 Sage Therapeutics shares in Q3 2025, an estimated $2.05M.
  • Gabelli & Co Investment Advisers first reported a position in Sage Therapeutics in Q2 2025 and held it in 1 quarter.
  • Gabelli & Co Investment Advisers's Sage Therapeutics position peaked at $2.05M in Q2 2025.
  • 5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.

Based on Gabelli & Co Investment Advisers's 13F filing for Q3 2025, filed 12 Nov 2025.